Results 211 to 220 of about 2,911,119 (244)

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Ca-A Cancer Journal for Clinicians, 2022
Sharon Elad, Noam Yarom, Yehuda Zadik
exaly  

Trends in kinase drug discovery: targets, indications and inhibitor design

Nature Reviews Drug Discovery, 2021
Misty M Attwood, Stefan Knapp
exaly  

Research Progress of Tropomyosin Receptor Kinase (TRK) Inhibitors

Chinese Journal of Organic Chemistry, 2022
Hong Liu, Yuanzheng Cheng, Chunpu Li, Zichao Xu, Junzhe Yang   +4 more
openaire   +1 more source

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Nature Medicine, 2022
Adriaan A Voors, Christiane Angermann Angermann, John R Teerlink   +2 more
exaly  

Loxo TRK inhibitor data wows oncologists

Nature Biotechnology, 2017
openaire   +2 more sources

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Nature Medicine, 2021
Barry A Borlaug, Dalane W Kitzman, Sanjiv J Shah   +2 more
exaly  

Repotrectinib. ALK/ROS1/TRK inhibitor, Treatment of solid tumors

Drugs of the Future, 2022
Zheshen Li, Letao Bo, Salehikram Talukder, Feng-Feng Ping, Zhe-Sheng Chen   +4 more
openaire   +1 more source

The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

, 2017
D. Hyman, T. Laetsch, S. Kummar, S. DuBois, A. Farago, A. Pappo, G. Demetri, W. El-Deiry, U. Lassen, A. Dowlati, M. Brose, V. Boni, B. Turpin, R. Nagasubramanian, S. Cruickshank, M. Cox, N. Ku, D. Hawkins, D. Hong, A. Drilon   +19 more
semanticscholar   +1 more source

Ansprechen von TRK-Inhibitor bestätigt

Gastro-News, 2018
openaire   +1 more source

Novel Macrocycle-Based Type-II TRK Inhibitors

Synfacts, 2022
openaire   +1 more source